Volastra Therapeutics

We’re Hiring: Director, Development Program Management, Oncology! Volastra Therapeutics is looking for a driven leader to join our team as Director of Development Program Management, Oncology. Reporting to the Chief Medical Officer, this role is important in managing our oncology development programs, ensuring smooth integration across functions, and driving key milestones. If you have experience working on clinical-stage oncology programs and want to make an impact in a fast-paced biotech environment, we’d love to hear from you: https://lnkd.in/eE7h-mCX #BiotechCareers #Oncology #ProgramManagement #PharmaJobs #VolastraTherapeutics #NowHiring #NYCJobs

Over the past five years, our team has focused on developing innovative therapies targeting #chromosomal_instability (CIN)—a major driver of cancer progression—to unlock a new frontier in #cancer treatment.   The groundbreaking work with our two #clinical stage, oral #KIF18A inhibitors is only the beginning—we’re continuing to push the boundaries to redefine what’s possible in #oncology.   Our Chief Executive Officer, Charles Hugh-Jones, MD, reflects on our remarkable journey and the promising future of targeting CIN to improve #patient outcomes. Check out his latest article about our progress over the past five years and what’s to come for Volastra! https://lnkd.in/eF_TBw8d

We’re thrilled to welcome our co-founder, Samuel Bakhoum, M.D., Ph.D., to the Volastra team as Chief Scientific Officer! Dr. Bakhoum is a renowned physician-scientist and leader in #cancer research, who has pioneered work in the field of #chromosomal_instability (CIN).   Learn more about Dr. Bakhoum and read the full press release here: https://lnkd.in/eiKfcjA4

We're Hiring a Senior Vice President of Legal, Compliance, and Operations! Volastra Therapeutics is seeking a strategic leader with deep expertise in the biotechnology industry to join our team. As the SVP of Legal, Compliance, and Operations, you will oversee our legal affairs, corporate compliance, and operational functions to drive efficiency and ensure we meet the highest regulatory and ethical standards. Are you ready to lead in a dynamic, fast-growing environment? Join us on our mission to innovate in oncology. 👉 Apply here: https://lnkd.in/eKfkMZQV #NowHiring #BiotechCareers #LegalJobs #Biotechnology #Oncology #VolastraTherapeutics #NYCJobs 

We’re excited to announce the US Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, our internally discovered #KIF18A inhibitor for the treatment of #patients with platinum-resistant high-grade serous #ovariancancer (HGSOC). This designation further underscores the potential of KIF18A inhibition to address the high unmet need in treating HGSOC and takes us one step closer to delivering new treatment options to patients. Read more about the news: https://lnkd.in/gBNtYTPW

In honor of #OvarianCancerAwarenessMonth, we are highlighting the role of #chromosomal_instability (CIN) in some of the most hard-to-treat cancers, including high-grade serous ovarian cancer (HGSOC). CIN is almost universally present in HGSOC and acts as a driver of tumor development and progression.   At Volastra, we’re developing new treatments for #ovarian cancer by leveraging #KIF18A inhibition to exploit CIN as a vulnerability of these cancers. For additional information on our Phase 1b study in HGSOC, visit https://bit.ly/4eiswGB, and for additional information on our Phase 1 study in a range of tumors (including ovarian), visit https://bit.ly/4ebScVs.

We are proud sponsors of this year’s Federation of American Societies for Experimental Biology (FASEB) Consequences of Aneuploidy Conference! Christina Eng, our Vice President, Biology, is on-site this week—be sure to connect with her while you are there! #ANESRC

In honor of #OvarianCancerAwarenessMonth, we are highlighting the role of #chromosomal_instability (CIN) in some of the most hard-to-treat cancers, including high-grade serous ovarian cancer (HGSOC). CIN is almost universally present in HGSOC and acts as a driver of tumor development and progression.   At Volastra, we’re developing new treatments for #ovarian cancer by leveraging #KIF18A inhibition to exploit CIN as a vulnerability of these cancers. For additional information on our Phase 1b study in HGSOC, visit https://bit.ly/4eiswGB, and for additional information on our Phase 1 study in a range of tumors (including ovarian), visit https://bit.ly/4ebScVs.

Our co-founder and scientific advisor, Dr. Samuel Bakhoum, was recently featured in Fierce Biotech for his pioneering work linking #chromosomal_instability (CIN) to #cancer progression. His groundbreaking research forms the backbone of our research strategy which exploits CIN to develop transformative treatments for cancer patients. Read the full article here: https://bit.ly/4g8NzgG

Earlier this week, the Volastra team came together for a fun-filled afternoon at Yankee Stadium. Taking a break from the office allowed us to relax and recharge, and to top it off, the Yankees won 9-1! ⚾️🌞 Here’s to continued teamwork, both on and off the field! Pictured: Cayley Gehnrich; Sarah Bettigole; Joseph Avallone; Derek Rookhuizen; Nazario Bosco; Song Chen; Charles Hugh-Jones; Scott Drutman MD PhD; Adriana Roopnariane; Maeve Morse-Seaverns; Linda Lee; Reka Letso; Cindy O.; Aaron Phillips; Jonathan Havel; Andrea Ozuna; Ryan Schulz; Christina Eng; Rachel Zolot Schwartz